[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, galcanezumab has been shown to be effective in reducing the number of monthly migraine headache days and improving quality of life in patients with both episodic and chronic migraine. Multiple randomized controlled trials and meta-analyses have demonstrated the efficacy of galcanezumab in reducing migraine frequency and improving patient outcomes. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]